NasdaqGM:GPCRPharmaceuticals
Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence
Why Structure Therapeutics (GPCR) Is Back on Investors’ Radar
Structure Therapeutics (GPCR) is drawing fresh attention after recent analyst commentary pointed to growing confidence in its obesity pipeline, including key trial progress for aleniglipron and a new licensing deal with Genentech.
The agreement with Genentech includes a US$100 million upfront payment and potential royalties, while analysts are watching upcoming clinical milestones such as the 44 week ACCESS II readout and a planned...